Sun et al. found that RTA-408 (Nrf2 activator) could inhibit osteoclastogenesis and prevent bone loss in ovariectomy-induced osteoporosis mice models via blocking STING dependent NF-κB signaling pathway (Sun et al., 2020). This evidence concerns the gene NFKB1 and osteoporosis.